SEC Company Response from Esperion Therapeutics, Inc. (ESPR) (CIK 0001434868) (ESPR) — Jan 14, 2016
Esperion Therapeutics, Inc. (ESPR) (CIK 0001434868)
Date: Jan. 14, 2016 · CIK: 0001434868 · Accession: 0001104659-16-089883
AI Filing Summary & Sentiment
File numbers found in text: 333-208701
Letter
ESPERION THERAPEUTICS, INC.
3891 Ranchero Drive
Ann Arbor, MI 48108
January 14, 2016
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Esperion Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-208701
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Esperion Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-208701) (the “Registration Statement”), so that it may become effective at 3:00 p.m. Eastern Time on January 19, 2016, or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
1.
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
2.
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
3.
the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Esperion Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm ESPERION THERAPEUTICS, INC. 3891 Ranchero Drive Ann Arbor, MI 48108 January 14, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Esperion Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-208701 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Esperion Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-208701) (the “Registration Statement”), so that it may become effective at 3:00 p.m. Eastern Time on January 19, 2016, or as soon thereafter as practicable. The Registrant hereby acknowledges that: 1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; 2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and 3. the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Esperion Therapeutics, Inc. By: /s/ Tim M. Mayleben Name: Tim M. Mayleben Title: President and Chief Executive Officer Cc: Mitchell S. Bloom, Esq. (Goodwin Procter LLP) Arthur R. McGivern, Esq. (Goodwin Procter LLP) [Signature Page to Request for Acceleration of Effectiveness]